Quantcast
Last updated on April 19, 2014 at 13:20 EDT

Latest Naloxone Stories

2013-09-16 12:27:24

In the news release, Zubsolv® Now Available in the U.S. for the Maintenance Treatment of Opioid Dependence, issued 16-Sep-2013 by Orexo U.S. over PR Newswire, we are advised by the company that the phone number in the fifth paragraph and the Orexo U.S., Inc. boilerplate, should read "1-855-ZUBSOLV" rather than "1-888-ZUBSOLV" as originally issued inadvertently. The complete, corrected release follows: Zubsolv® Now Available in the U.S. for the Maintenance Treatment of Opioid Dependence...

2013-09-10 08:26:24

New Public Health Initiative Helps Reveal the Real Situation About Growing National Epidemic RICHMOND, Va., Sept. 10, 2013 /PRNewswire/ -- Michael "The Situation" Sorrentino today helped launch a new public health initiative titled "Reset Reality" designed to increase knowledge and understanding of the prevalence, science and treatment of opioid prescription painkiller addiction - a condition he personally struggled with until finally seeking help in 2012. Working in partnership...

2013-08-28 20:21:25

Performance Art Meets Political Action to Prevent Accidental Overdose! A Funeral March From CRI-HELP/SOCORRO past L.A. County Morgue to USC Medical Center to Remember Lives Lost and to Educate About Solutions to the Overdose Crisis LOS ANGELES, Aug. 28, 2013 /PRNewswire-USNewswire/ -- Alcohol Justice is reporting that the Los Angeles chapter of A New PATH will join the Drug Policy Alliance, Cri-Help, Inc., Paso Por Paso, Broken No More, Alcohol Justice and other organizations...

2013-08-21 08:26:11

Partnership to use Lightlake Therapeutics novel intranasal naloxone application to reverse overdoses LONDON, Aug. 21, 2013 /PRNewswire/ -- Lightlake Therapeutics Inc., ("Lightlake" or the "Company") (OTC BB: LLTP), a biopharmaceutical company developing addiction treatments based on its expertise in opioid antagonists, announced today the Company is moving forward in expanding access to medication for the treatment of opioid overdose with the National Institute on Drug Abuse...

2013-08-05 08:26:31

LONDON, Aug. 5, 2013 /PRNewswire/ -- Lightlake Therapeutics Inc., ("Lightlake" or the "Company") (OTC BB: LLTP), a biopharmaceutical company developing addiction treatments based on its expertise in opioid antagonists, announced today that it has retained KCSA Strategic Communications ("KCSA"), a leading New York-based communications firm, to direct the Company's investor and public relations programs. KCSA will deploy an integrated investor and public relations campaign to...

2013-08-01 08:32:43

First buprenorphine naloxone buccal film for the maintenance treatment of opioid dependence RALEIGH, N.C., Aug. 1, 2013 /PRNewswire/ -- BioDelivery Sciences International, Inc. (Nasdaq: BDSI) announced that yesterday it submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for BUNAVAIL (buprenorphine naloxone buccal film) for the maintenance treatment of opioid dependence. Under the 505(b)(2) regulatory statute, BUNAVAIL will be subject to a ten month...

2013-07-05 08:22:07

Designed to offer physicians and patients a new choice for opioid dependence, Zubsolv's formulation of buprenorphine and naloxone has higher bioavailability, a fast dissolve time, smaller tablet size and a new flavor NEW YORK, July 5, 2013 /PRNewswire/ -- Orexo U.S., Inc. announced that it has received approval from the U.S. Food and Drug Administration (FDA) for Zubsolv (buprenorphine and naloxone) sublingual tablets (CIII). Zubsolv is indicated for the maintenance treatment of...

2013-06-10 16:25:51

Drug users can be trained to use overdose antidote naloxone and save lives, says international public health coalition VILNIUS, Lithuania, June 10, 2013 /PRNewswire-USNewswire/ -- Drug users, their families, and friends, need to know how to use, access, and advocate for the life-saving drug naloxone, said the Open Society Foundations and an international coalition of public health organizations today who launched the website naloxoneinfo.org. The coalition includes the Open...

2013-06-10 08:29:19

BUNAVAIL NDA submission continues on target for mid-summer 2013 RALEIGH, N.C., June 10, 2013 /PRNewswire/ -- BioDelivery Sciences International, Inc. (Nasdaq: BDSI) announced today that it engaged in a positive pre-New Drug Application (NDA) meeting with the U.S. Food and Drug Administration (FDA) regarding BUNAVAIL for the maintenance treatment of opioid dependence. (Logo: http://photos.prnewswire.com/prnh/20110217/CL49801LOGO ) The positive outcome of the pre-NDA meeting...

2013-05-03 04:20:41

BRENTWOOD, England, May 3, 2013 /PRNewswire/ -- - World's first licensed naloxone product for use by non-healthcare profession individuals in a community setting - Prenoxad Injection is a pre-filled syringe containing 1mg/ml naloxone hydrochloride solution for injection Martindale Pharma, a leader in the manufacture and supply of specialty pharmaceuticals , is pleased to announce the UK launch of Prenoxad Injection, the world's...